Yuhong Zeng

Cost-effectiveness analysis of efavirenz versus ainuovirine in people living with HIV initiating first-line combination antiretroviral therapy

Abstract Background Ainuovirine (ANV), a new non-nucleoside reverse transcriptase inhibitor, has been shown to have comparable effectiveness to efavirenz (EFV) with fewer adverse events. However, evidence on the cost-effectiveness of replacing EFV-based regimens with ANV-based regimens remains limited, particularly wit...